Driehaus Capital Management LLC Has $9.82 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Driehaus Capital Management LLC lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 71,295 shares of the company’s stock after selling 294 shares during the quarter. Driehaus Capital Management LLC’s holdings in Neurocrine Biosciences were worth $9,815,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its position in shares of Neurocrine Biosciences by 18.3% in the fourth quarter. The Manufacturers Life Insurance Company now owns 116,955 shares of the company’s stock worth $15,410,000 after purchasing an additional 18,070 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Neurocrine Biosciences by 3.5% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 252,565 shares of the company’s stock valued at $34,834,000 after acquiring an additional 8,630 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Neurocrine Biosciences by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 9,710,328 shares of the company’s stock valued at $1,279,433,000 after acquiring an additional 150,485 shares during the last quarter. Perceptive Advisors LLC raised its holdings in Neurocrine Biosciences by 70.1% during the fourth quarter. Perceptive Advisors LLC now owns 270,794 shares of the company’s stock worth $35,680,000 after acquiring an additional 111,552 shares in the last quarter. Finally, Van ECK Associates Corp boosted its position in Neurocrine Biosciences by 1,325.5% during the first quarter. Van ECK Associates Corp now owns 92,243 shares of the company’s stock valued at $12,722,000 after purchasing an additional 85,772 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Activity at Neurocrine Biosciences

In related news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the transaction, the director now owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director William H. Rastetter sold 14,250 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the transaction, the director now owns 37,491 shares of the company’s stock, valued at $5,499,554.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Matt Abernethy sold 14,100 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $150.38, for a total transaction of $2,120,358.00. Following the sale, the chief financial officer now owns 31,528 shares in the company, valued at $4,741,180.64. The disclosure for this sale can be found here. Insiders have sold 61,798 shares of company stock valued at $9,274,196 over the last ninety days. 4.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Citigroup boosted their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Royal Bank of Canada dropped their price target on shares of Neurocrine Biosciences from $143.00 to $136.00 and set a “sector perform” rating on the stock in a research report on Thursday, August 29th. HC Wainwright reissued a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, August 29th. Barclays dropped their target price on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Finally, Oppenheimer lifted their price target on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $162.20.

Neurocrine Biosciences Trading Down 0.8 %

Shares of NBIX opened at $115.06 on Monday. The firm’s 50 day moving average is $135.50 and its 200-day moving average is $137.45. Neurocrine Biosciences, Inc. has a 12 month low of $103.63 and a 12 month high of $157.98. The stock has a market capitalization of $11.58 billion, a PE ratio of 31.70 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The firm had revenue of $590.20 million during the quarter, compared to analyst estimates of $545.98 million. During the same quarter in the previous year, the firm posted $0.95 earnings per share. Neurocrine Biosciences’s quarterly revenue was up 30.4% compared to the same quarter last year. Equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.